Andere talen Revvity, Inc.

Aandelen

Beurs gesloten - Nyse Andere beurzen 22:00:01 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
102,6 ^USD	+0,13%		-0,08%	-6,14%

30/04	REVVITY, INC. : TD Cowen ontvangt een koopadvies	ZM
30/04	REVVITY, INC. : JPMorgan Chase handhaaft het Neutraal advies	ZM

Revvity : Q1 2024 Earnings Transcript	30/04
Revvity beats quarterly estimates on demand for diagnostic equipment	29/04
Revvity Q1 Adjusted Earnings, Revenue Down; Lowers 2024 Revenue Guidance	29/04
Earnings Flash (RVTY) REVVITY Reports Q1 Revenue $649.9M, vs. Street Est of $647.5M	29/04
Revvity: Q1 Earnings Snapshot	29/04
Earnings Flash (RVTY) REVVITY Posts Q1 EPS $0.98, vs. Street Est of $0.94	29/04
Revvity Announces Financial Results for the First Quarter of 2024	29/04
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024	29/04
Revvity, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Revvity Board Declares Quarterly Dividend	25/04
Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024	25/04
Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings	25/04
Revvity to Present at BofA Securities 2024 Health Care Conference	25/04
Early Check Newborn Screening Study Taps Revvity to Provide Genome Sequencing	25/04
Declaration of Voting Results by Revvity, Inc	24/04
Revvity Unveils a New Era of Automated Tuberculosis Testing	24/04
Revvity Unveils A New Era of Automated Tuberculosis Testing	24/04
Revvity Signals Software's New Synergy Solution Redefines Collaboration between Pharma and Contract Partners	16/04
Revvity Signals Software’s New Synergy Solution Redefines Collaboration Between Pharma and Contract Partners	15/04
Revvity To Hold Earnings Call on Monday, April 29, 2024	04/04

Geen resultaten voor deze zoekopdracht